NEW YORK, Jan. 29 /PRNewswire/ -- According to the American Cancer Association, prostate cancer affects one in six men in the U.S. and is the second leading cause of cancer deaths in men. When caught and treated early, survival rates can be more than 90 percent, making swift treatment key.
(See video from International HIFU at: http://media.medialink.com/WebNR.aspx?story=36220)
Existing treatments however, can be limited and affect quality of life due to significant side effects, including loss of muscle mass, depression, decreased mental acuity and impotence. Now a High Intensity Focused Ultrasound (HIFU) procedure, available in 33 countries outside the US including Europe, is being tested in US Phase III clinical trials. HIFU is a minimally invasive procedure that uses the Sonablate(R) 500 ultrasound device to destroy cancerous tissue with focused sound waves.
By focusing sound waves in a targeted area, HIFU can rapidly increase the temperature in the focal zone, causing tissue destruction. This procedure is radiation-free and doesn't preclude any other treatment options.
For more information regarding the risks and benefits associated with HIFU, go to www.InternationalHIFU.com.
NOTE: Sonablate(R) 500 is not approved for use in the U.S. It remains investigational in the U.S. and is being studied as a prostate cancer treatment in clinical trials in the U.S. The FDA has made no decision as to the safety or efficacy of Sonablate(R) 500 for the treatment of prostate cancer. USHIFU is a worldwide leader in the development, distribution and use of minimally invasive high intensity focused ultrasound technologies. International HIFU is the entity through which USHIFU conducts its international business operations and makes the HIFU technologies available to US patients at centers outside the United States where such technologies are approved.
Registered journalists can access video, audio, text, graphics and photos for free and unrestricted use at http://www.mediaseed.tv.
|SOURCE Medialink; International HIFU|
Copyright©2009 PR Newswire.
All rights reserved